Lower cumulative incidence reported for two-year physician-scored toxicity and late-grade \u22652 toxicity with MRI guidance<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, Nov. 27, 2024 (HealthDay News) — Magnetic resonance imaging (MRI) guidance for aggressive margin reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces two-year toxic effects, according to a study published online Nov. 13 in European Urology<\/em>.<\/p>\n Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted a secondary analysis of a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer to compare the impact of AMR with MRI guidance versus computed tomography (CT) guidance.<\/p>\n The researchers found that the cumulative incidence of two-year physician-scored toxicity, defined as grade \u22652 genitourinary (GU) and gastrointestinal (GI) toxic effects, were lower with MRI guidance. The cumulative incidence rates of late grade \u22652 toxicity at two years were 27 versus 51 percent for MRI- versus CT-guided SBRT for GU toxicity and 1.4 versus 9.5 percent for GI toxicity. The odds of a clinically relevant deterioration in bowel function according to the Expanded Prostate Cancer Index Composite-26 score and in the Sexual Health Inventory in Men score were significantly lower with MRI-guided SBRT (odds ratios, 0.444 and 0.366, respectively). The odds of a deterioration for other quality-of-life metrics did not differ significantly.<\/p>\n “This study adds strong evidence that the enhanced precision and accuracy afforded by MRI-guided SBRT leads to significantly fewer urinary, bowel, and sexual side effects for men receiving prostate SBRT,” Kishan said in a statement.<\/p>\n Several authors disclosed ties to the pharmaceutical and medical device industries.<\/p>\n